ACROFAN

Kainos Medicine Is at the End of Phase III Clinical Trials of Anti-HIV Drug in China

Published : Friday, February 28, 2020, 2:47 pm
ACROFAN=Seunghee Shin | seunghee.shin@acrofan.com | SNS
As an anti-HIV drug developed by Kainos Medicine, Inc., is entering the final stage of phase III clinical trials in China, royalty sales are expected to be high through commercial sales.

Kainos Medicine, which is planning to merge with Hana Financial Eleventh Special Purpose Acquisition Co (SPAC), announced that it is ready for the injection to the last patient in the first half of this year as the Phase III clinical trials of the anti-HIV drug, KM-023, proceeded smoothly. The technology of KM-023 had been transferred to a Chinese pharmaceutical company, Jiangsu Aidea Pharmaceutical.

 


Kainos Medicine stated that the safety of KM-023 is competitive and will be able to replace conventional drugs such as Efavirenz and Rilpivirin. Contrary to the existing anti-HIV drugs showing side effects related to birth defects and degenerative brain diseases, KM-023 has no related side effects in Phase I clinical trial and has been shown to have excellent antiviral effects. And another positive factor is that even if 25% of the amount is used, it shows the same effect as the existing drug.

Kainos Medicine transferred the technology of KM-023 to Jiangsu Aidea Pharmaceutical in 2014 after completing the first phase of clinical trials in Korea. In response, the China Food and Drug Administration (CFDA) has designated KM-023 as a fast track review in 2017, given the increasing number of patients who give up treatment due to expensive treatment costs. After analyzing the results of Phase I clinical trials, Phase IIA was shortly progressed in recognition of its excellent efficacy as a therapeutic agent.

Currently, KM-023's copyright in China is owned by Jiangsu Aidea Pharmaceutical, and Kainos Medicine is a global distributor. Kainos Medicine received a full $1.7 million as licensing fees from Jiangsu Aidea Pharmaceutical in 2017, and will receive 2% of the sales of single-and complex-agents as royalties.

Kainos Medicine said, "There is a very low dropout rate in phase III clinical trials that are currently underway, so the expectation of KM-023 is high. In addition, as part of the Chinese government's pharmaceutical innovation business policy, KM-023 plans to sell prototypes under the active support and management of the Chinese government. And we aim to have a 30% market share within three years after launch."



Copyright © acrofan All Right Reserved


    Acrofan     |     Contact Us : guide@acrofan.com     |     Contents API : RSS

Copyright © Acrofan All Right Reserved